Audentes Therapeutics is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases.

We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to progress programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown.

We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

Stock Information